A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).

Lee, Choong-Kun; Cheon, Jaekyung; Chon, Hong Jae; Kim, Min Hwan; Kim, Jin Won; Lee, Myung Ah; Park, Hyung Soon; Kang, Myoung Joo; Jang, Joung-Soon; Choi, Hye Jin

doi:10.1200/JCO.2021.39.15_suppl.TPS4161

Detailed Information

Cited 0 time in webofscience

Cited 0 time in scopus

Metadata Downloads

A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).

Authors: Lee, Choong-Kun; Cheon, Jaekyung; Chon, Hong Jae; Kim, Min Hwan; Kim, Jin Won; Lee, Myung Ah; Park, Hyung Soon; Kang, Myoung Joo; Jang, Joung-Soon; Choi, Hye Jin

Issue Date: May-2021

Publisher: LIPPINCOTT WILLIAMS & WILKINS

Citation: JOURNAL OF CLINICAL ONCOLOGY, v.39, no.15

Journal Title: JOURNAL OF CLINICAL ONCOLOGY

Volume: 39

Number: 15

URI: https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54517

DOI: 10.1200/JCO.2021.39.15_suppl.TPS4161

ISSN: 0732-183X
1527-7755

Files in This Item: There are no files associated with this item.

Appears in Collections: College of Medicine > College of Medicine > 1. Journal Articles

Show full item record

qrcode

Altmetrics

Total Views & Downloads

STATISTICS: Total View :7,502,175; Today View :2,821

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Altmetrics

Total Views & Downloads

BROWSE